A Sinopharm affiliate said on Friday that the two COVID-19 vaccines developed by China National Pharmaceutical Group (Sinopharm) subsidiaries have hit a combined 100 million doses of supply worldwide.
According to China National Biotec Group Company (CNBG), over 80 million doses of the two vaccines were administered.
An annual capacity of 1 billion jabs could be reached in 2021 and Sinopharm aims to expand capacity to 3 billion doses per year, without specifying the timeframe for the target.
On Monday, another Chinese vaccine maker Sinovac Biotech said it had supplied 160 million doses of its COVID-19 vaccine to 18 countries and regions, including China, with over 70 million shots injected.
Including the vaccine from CanSino Biologics Inc, a total of 4 vaccines have been approved in China for general public use. A fifth vaccine developed by the Institute of Microbiology Chinese Academy of Sciences has gained clearance for limited emergency use.